Evidence map›Paper›PMID 20515733›Full record

ReviewFrontiers in bioscience (Landmark edition)2010

Focal adhesion kinase and p53 signal transduction pathways in cancer.

Vita M Golubovskaya, William Cance

Open access · bronzeAbstract readReview
In one paragraph

Review in Frontiers in bioscience (Landmark edition), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Polymeric Hydrogels for In Vitro 3D Ovarian Cancer Modeling.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Vita M GolubovskayaDepartment of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. Vita.Golubovskaya@Roswellpark.org
William Cance
Roswell Park Comprehensive Cancer Center · US

Funding

FOCAL ADHESION KINASE--TUMOR BIOLOGY AND THERAPEUTICSR01CA065910 · NCI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI MARLOWE, TIMOTHY A · 1996 to 2019
$6.3M
NCI NIH HHS R01 CA065910
6 · The paper itself

Abstract

Human cancer is characterized by a process of tumor cell motility, invasion, and metastasis. One of the critical tyrosine kinases that is linked to these processes of tumor invasion and survival is the Focal Adhesion Kinase (FAK). Our laboratory was the first to isolate FAK from human tumors, and we had demonstrated that FAK mRNA was up-regulated in invasive and metastatic human breast and colon cancer samples. We have cloned FAK promoter and have found that FAK promoter contains p53 binding sites, and that p53 inhibits FAK transcription and regulates its expression in tumor samples. In addition, we have found a high correlation between FAK overexpression and p53 mutations in 600 population-based series of breast cancer patients. found that N-myc binds FAK promoter and induces FAK transcription in neuroblastoma cells. Thus, this review will be focused on FAK and p53 signal transduction pathways in cancer.

Indexed as

Signal TransductionAntineoplastic AgentsFocal Adhesion Protein-Tyrosine KinasesGene Expression Regulation, NeoplasticHumansMutationNeoplasmsPromoter Regions, GeneticProtein BindingTumor Suppressor Protein p53Antineoplastic AgentsFocal Adhesion Protein-Tyrosine KinasesTumor Suppressor Protein p53

Identifiers

PMID20515733
PMCPMC3136041
OpenAlexW1581002015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.